Starting out of China, IBT Global is a rising player in Digital Therapeutics (DTx) with an experienced cross-functional team operating at the intersection of neuroscience and software technology. IBT global develops patient-facing software applications that provide better outcomes for patients with proven clinical benefit.

The ATLATL Center for Innovation & Research is a global innovation research and development center located in the heart of multiple prestigious science parks, creating a new life sciences ecosystem by partnering with entrepreneurs, investors, pharmaceutical companies, and service companies.

Dr. Wei Sun, Founder and Chairman of IBT, made the following statement: “IBT’s team focuses on developing precise Digital Therapeutics for brain health globally and we are pleased and honored to be partnering with ATLATL to develop precise digital therapeutics for brain health with advanced AI technologies.”

CEO of ATLATL, PC Zhu, expressed how ATLATL aims to make a significant contribution to the global brain health industry: “ATLATL is known for its infrastructure and operational management, specialized core facilities and on-site interactive research services. IBT is widely acknowledged for its ability to develop accurate digital therapeutics using advanced AI technologies and we are honored to work with IBT to enhance global innovation in brain health.”

Justin Jia, CTO of IBT and CEO of IBT Global said: “We are thrilled to partner with ATLATL, leveraging its extensive R&D services and vast bio-tech networks, as we at IBT work towards our mission of creating cutting-edge AI-powered digital therapeutics. Our goal is to provide effective clinical solutions for individuals battling mental disorders.”